Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

The GLP-1 arena has turned into a boxing match between heavyweights Novo Nordisk and Eli Lilly as the two pharma giants ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

David Petrus IbarsIn the same way weight varies from person to person, so do the best weight loss strategies. While some ...

MariTide, a new drug from Amgen, helped some people with obesity lose up to 20% of their body weight. In a phase 2 trial, a new GLP-1 drug helped people lose up to 20% of their body weight over a year ...

Both well-established and small, clinical-stage pharma companies are investing heavily to be able to someday compete with ...

Amgen Inc. (NASDAQ: AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company announced full results from Part 1 of the Phase 2 study of MariTide ...

MariTide isn't approved, but even if it is, if it doesn't shake concerns related to side effects, then there may not be strong demand for it. Has Amgen become a bad buy on this news?

Maridebart cafraglutide showed promising results in weight loss, offering a monthly treatment option for obesity with ...

MariTide (maridebart cafraglutide; previously AMG 133) has emerged as one of Amgen's most promising pipeline projects thanks to its potential to offer once-monthly or even less frequent dosing, in ...